^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

ARL2 (ADP Ribosylation Factor Like GTPase 2)

i
Other names: ADP Ribosylation Factor Like GTPase 2, ADP-Ribosylation Factor-Like Protein 2, ADP-Ribosylation Factor-Like 2, ARFL2, MRCS1, ARL2
Associations
Trials
1m
Repeatability of semi-quantitative [68Ga]Ga-FAPI-46 PET/CT measurements in pancreatobiliary cancers: a test-retest study. (PubMed, Eur J Nucl Med Mol Imaging)
Semi-quantitative measurements of [68Ga]Ga-FAPI-46 PET/CT have an excellent repeatability and can potentially be used in future studies to assess treatment response in pancreatobiliary cancers.
Journal
|
FAP (Fibroblast activation protein, alpha) • ARL2 (ADP Ribosylation Factor Like GTPase 2)
3ms
Bovine tubulin cofactor D (TBCD) disrupts tubulin dimers and inhibits tumor growth via the TNF-α signaling pathways-mediated ROS production. (PubMed, Int J Biol Macromol)
Specific interaction of bTBCD with β-tubulin destabilizes tubulin dimers and causes cell death via activation of the TNF-α signaling pathway. As a proof of concept, our findings suggest that the bTBCD, as a microtubule disturber, could potentially be applied to gene therapy for tumors, particularly those resistant to existing MTAs.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • ARL2 (ADP Ribosylation Factor Like GTPase 2)
|
vincristine
5ms
Interpretable Multi-Cancer Early Detection Using SHAP-Based Machine Learning on Tumor-Educated Platelet RNA. (PubMed, Diagnostics (Basel))
The integration of interpretable ML with platelet RNA data revealed robust biomarkers and context-dependent regulatory patterns relevant to early cancer detection. The proposed framework supports the potential of TEPs as a non-invasive, information-rich medium for early cancer screening.
Journal
|
ARL2 (ADP Ribosylation Factor Like GTPase 2) • DHCR7 (7-Dehydrocholesterol Reductase)
over1year
The impact of introducing deep learning based [18F]FDG PET denoising on EORTC and PERCIST therapeutic response assessments in digital PET/CT. (PubMed, EJNMMI Res)
Although comparing similar PET images is preferable for therapy response assessment, the comparison between a standard [18F]FDG PET and an AI denoised half-duration PET is feasible and seems clinically satisfactory.
Journal • FDG PET
|
ARL2 (ADP Ribosylation Factor Like GTPase 2)
over2years
Retraction Note: MiR-195-5p inhibits the cell migration and invasion of cervical carcinoma through suppressing ARL2. (PubMed, Eur Rev Med Pharmacol Sci)
https://www.europeanreview.org/article/19764 This manuscript has been withdrawn. The Publisher apologizes for any inconvenience this may cause.
Journal
|
ARL2 (ADP Ribosylation Factor Like GTPase 2) • MIR195 (MicroRNA 195)
over2years
Quantitative and clinical implications of the EARL2 versus EARL1 [F]FDG PET-CT performance standards in head and neck squamous cell carcinoma. (PubMed, EJNMMI Res)
Using the EARL2 method for PET image reconstruction resulted in higher SUV and SUR compared to EARL1, with nodal upstaging in a significant number of patients.
Journal • FDG PET
|
ARL2 (ADP Ribosylation Factor Like GTPase 2) • MED23 (Mediator Complex Subunit 23)
over2years
Sensitivity of an AI method for [F]FDG PET/CT outcome prediction of diffuse large B-cell lymphoma patients to image reconstruction protocols. (PubMed, EJNMMI Res)
Our CNN-based outcome predictions are affected by the applied reconstruction protocols, yet in a predictable manner. Image-based harmonization is a suitable approach to harmonize CNN predictions across image reconstruction protocols.
Journal • FDG PET
|
ARL2 (ADP Ribosylation Factor Like GTPase 2)
over2years
Long Non-Coding RNA ZSCAN16-AS1 Promotes the Malignant Progression of Melanoma Through Regulating the miR-503-5p/ARL2 Axis. (PubMed, Clin Cosmet Investig Dermatol)
These results demonstrated the role and molecular mechanism of ZSCAN16-AS1 in the occurrence and development of melanoma. Therefore, ZSCAN16-AS1 may be used as a specific biomarker in the diagnosis and treatment of melanoma patients.
Journal
|
MIR503 (MicroRNA 503) • ARL2 (ADP Ribosylation Factor Like GTPase 2)
almost3years
Imaging and Pathologic Evaluation of Cryoablation of Woodchuck (Marmota monax) Hepatocellular Carcinoma. (PubMed, Comp Med)
Partial cryoablation of tumors produced coagulative necrosis with well-defined ablation margins at 14 d. Cauterization appeared to prevent hemorrhage after cryoablation of hypervascular tumors. Our findings indicate that woodchucks with HCC may provide a predictive preclinical model for investigating ablative modalities and developing new combination therapies.
Journal
|
ARL2 (ADP Ribosylation Factor Like GTPase 2)
over3years
Circ_0085616 contributes to the radio-resistance and progression of cervical cancer by targeting miR-541-3p/ARL2 signaling. (PubMed, Histol Histopathol)
Circ_0085616 contributed to the radio-resistance and progression of cervical cancer partly through mediating the miR-541-3p/ARL2 axis.
Journal
|
ARL2 (ADP Ribosylation Factor Like GTPase 2)
over3years
External validation: a simulation study to compare cross-validation versus holdout or external testing to assess the performance of clinical prediction models using PET data from DLBCL patients. (PubMed, EJNMMI Res)
In case of small datasets, it is not advisable to use a holdout or a very small external dataset with similar characteristics. A single small testing dataset suffers from a large uncertainty. Therefore, repeated CV using the full training dataset is preferred instead. Our simulations also demonstrated that it is important to consider the impact of differences in patient population between training and test data, which may ask for adjustment or stratification of relevant variables.
Journal
|
ARL2 (ADP Ribosylation Factor Like GTPase 2)
over3years
Journal
|
ARL2 (ADP Ribosylation Factor Like GTPase 2)